Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts

Evguenia Krastinova, Remonie Seng, Patrick Yeni, Jean-Paul Viard, Daniel Vittecoq, Caroline Lascoux-Combe, Erwan Fourn, Golriz Pahlavan, Jean François Delfraissy, Cecile Goujard, Laurence Meyer, ANRS PRIMO and COPANA Cohorts

Abstract

Objective: Guidelines for initiating HIV treatment are regularly revised. We explored how physicians in France have applied these evolving guidelines for ART initiation over the last decade in two different situations: chronic (CHI) and primary HIV-1 infection (PHI), since specific recommendations for PHI are also provided in France.

Methods: Data came from the ANRS PRIMO (1267 patients enrolled during PHI in 1996-2010) and COPANA (800 subjects enrolled at HIV diagnosis in 2004-2008) cohorts. We defined as guidelines-inconsistent during PHI and CHI, patients meeting criteria for ART initiation and not treated in the following month and during the next 6 months, respectively.

Results: ART initiation during PHI dramatically decreased from 91% of patients in 1996-99 to 22% in 2007 and increased to 60% in 2010, following changes in recommendations. In 2007, however, after the CD4 count threshold was raised to 350 cells/mm(3) in 2006, only 55% of the patients with CD4≤350 were treated and 66% in 2008. During CHI, ART was more frequently initiated in patients who met the criteria at entry (96%) than during follow-up: 83% when recommendation to treat was 200 and 73% when it was 350 cells/mm(3). Independent risk factors for not being treated during CHI despite meeting the criteria were lower viral load, lower educational level, and poorer living conditions.

Conclusion: HIV ART initiation guidelines are largely followed by practitioners in France. What can still be improved, however, is time to treat when CD4 cell counts reach the threshold to treat. Risk factors for lack of timely treatment highlight the need to understand better how patients' living conditions and physicians' perceptions influence the decision to initiate treatment.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Change over time of ART…
Figure 1. Change over time of ART initiation during primary infection according to CD4 count (≤350; 351–500; >500 cells/mm3); the ANRS PRIMO study.

References

    1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, et al. (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315: 1194–1199.
    1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860.
    1. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al. (1996) Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 276: 146–154.
    1. Delfraissy JF, editor (2002) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Paris: Edition Flammarion. 1–280 p.
    1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, et al. (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288: 222–235.
    1. Hammer SM, Saag MS, Schechter M, Montaner JS (2006) Schooley RT, et al (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296: 827–843.
    1. Yeni PG (2006) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d’experts. Paris: Edition Flammarion. 1–368.
    1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283–2296.
    1. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. (2008) Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197: 1133–1144.
    1. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363: 257–265.
    1. Hammer SM, Eron JJ Jr, Reiss P (2008) Schooley RT, Thompson MA, et al (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555–570.
    1. Yeni P (2008) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d’experts. Paris: La documentation francaise.
    1. Yeni P (2010) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d’experts. Paris: La documentation française. Available: . Accessed: 3 Jun 2013.
    1. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321–333.
    1. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352–1363.
    1. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, et al. (2007) Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21: 1185–1197.
    1. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815–1826.
    1. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, et al. (2011) When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 154: 509–515.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2012) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available: . Accessed: 3 Jun 2013.
    1. World Health Organisation. (2010) Antiretroviral therapy for HIV infection in adults and adolescents Recommendations for a public health approach. Available: . 1–156. Accessed: 3 Jun 2013.
    1. European AIDS Clinical Society Guidlines (2011) European AIDS Clinical Society. Available: . Accessed: 3 Jun 2013.
    1. Asboe D, Aitken C, Boffito M, Booth C, Cane P, et al. (2012) British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 13: 1–44.
    1. Troude P, Chaix ML, Tran L, Deveau C, Seng R, et al. (2009) No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 23: 1261–1267.
    1. Rachas A, Warszawski J, le Chenadec J, Legeai C, Teglas JP, et al... (2012) Does Pregnancy Affect the Early Response to cART? AIDS.
    1. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, et al. (2009) Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. Can J Surg 52: 92–97.
    1. Leung DY, Hallani H, Lo ST, Hopkins AP, Juergens CP (2007) How compliant are we with guidelines for coronary angiography in clinical practice? Intern Med J 37: 699–704.
    1. Fervers B, Carretier J, Bataillard A (2010) Clinical practice guidelines. J Visc Surg 147: e341–349.
    1. Cabana MD, Rushton JL, Rush AJ (2002) Implementing practice guidelines for depression: applying a new framework to an old problem. Gen Hosp Psychiatry 24: 35–42.
    1. Cabana MD, Davis MM (2002) Improving physician adherence to cholesterol management guidelines. Manag Care 11: 18–22.
    1. Gnavi R, Picariello R, la Karaghiosoff L, Costa G, Giorda C (2009) Determinants of quality in diabetes care process: The population-based Torino Study. Diabetes Care 32: 1986–1992.
    1. Robert JRC, Poutignat N, Fagot-Campagna A, Weill A, Rudnichi A, et al... (2009) Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001. Bull Epidémiol Hebd 455–460.
    1. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, et al. (2003) The quality of health care delivered to adults in the United States. N Engl J Med 348: 2635–2645.
    1. Final Report European Core Indicators in Diabetes Project (2008) European Commission Available: .Accessed: 3 Jun 2013.
    1. Wandeler G, Keiser O, Hirschel B, Gunthard HF, Bernasconi E, et al. (2011) A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One 6: e27903.
    1. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, et al. (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282: 1458–1465.
    1. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, et al. (2009) Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 64: 599–606.
    1. Preau M, Protopopescu C, Raffi F, Rey D, Chene G, et al. (2012) Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability. AIDS Care 24: 434–443.
    1. Backlund L, Skaner Y, Montgomery H, Bring J, Strender LE (2004) The role of guidelines and the patient's life-style in GPs' management of hypercholesterolaemia. BMC Fam Pract 5: 3.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner